Multiplai Health

MultiplAI Health is a preventive medicine company developing a blood screening test for the early detection of cardiovascular and other complex diseases. Founded in 2019 by cardiologist Dr. Santiago Miriuka, molecular biologist Dr. Charlie Luzzani, and Mark Ramondt, the company was inspired by Ramondt's personal experience of having a preventable heart attack at age 35, despite being a patient of Dr. Miriuka. This event motivated them to develop a more accurate and accessible screening method than traditional risk factors like cholesterol and blood pressure.

The company's core technology leverages RNA sequencing and artificial intelligence to analyze a single blood sample. This "liquid biopsy" approach identifies molecular changes that signal an increased risk of a major cardiovascular event before physical symptoms appear. The process creates a detailed, 20GB data file from each sample, which is then condensed into a smaller, formatted "snapshot" for rapid algorithmic analysis. This allows the technology to provide a highly accurate risk assessment that is also affordable and scalable.

MultiplAI Health launched in the UK in 2020, supported by the Illumina Accelerator Cambridge, to leverage the country's expertise in genomics and AI. The company is headquartered in London with operations in Cambridge (UK), the US, and Buenos Aires, Argentina. In March 2024, MultiplAI Health entered into a business combination agreement with OmnigenicsAI and APx Acquisition Corp. I, a special purpose acquisition company (SPAC). The merger, which values the combined entity at approximately $340 million, aims to create a publicly traded, global AI-driven genomics platform listed on Nasdaq under the ticker "OMNI".

The company's business model targets healthcare providers, including private and public primary care, government healthcare systems, and pharmaceutical companies. By enabling timely intervention, the technology aims to reduce the financial and personal burden of cardiovascular disease, the world's leading cause of death.

Keywords: RNA sequencing, liquid biopsy, cardiovascular disease, preventive medicine, AI diagnostics, genomic screening, precision medicine, blood testing, disease detection, transcriptomics, bioinformatics, heart attack prevention, proactive health, complex diseases, risk assessment, health data platform, AI in healthcare, early detection, genomics, biotechnology